Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients
New Pricing Kicks In 1 January 2024
Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.
You may also be interested in...
Generics Bulletin previews the biggest events and changes for industry in the coming month.
Civica is set to provide biosimilar insulins to the state of California through its CalRx program, following approval from the US Food and Drug Administration.
Multiple payment models, including differential pricing for pooled purchases, and technology-based healthcare platforms are some of the ways to build a patient-centric ecosystem said officials from Roche, VCs and non-government bodies at a recent conference